Clinical Study On Gexia Zhuyu Decoction In The Treatment Of Chemoembolization Syndrome Of Qi Stagnation And Blood Stasis Type After Tace For Hepatocellular Carcinoma

Objective: To observe the clinical efficacy of Gexia Zhuyu Decoction in the treatment of embolism syndrome after TACE of primary liver cancer(qi stagnation and blood stasis type)and the remission of symptoms,and to objectively evaluate its efficacy and safety compared with the ordinary treatment group,so as to provide clinical research basis for Gexia Zhuyu Decoction in the treatment of embolism syndrome after TACE of liver cancer.Methods:fifty nine patients with TACE after primary liver cancer were collected from the Department of oncology,the First Affiliated Hospital of Hunan University of traditional Chinese medicine.59 patients were randomly divided into control group and observation group,29 cases in control group and 30 cases in observation group.There was no difference in gender,age and stage between the two groups(P > 0.05).The control group was given conventional western medicine symptomatic treatment,and the observation group was given Gexia Zhuyu Decoction on the basis of the control group.After two courses of treatment,the liver(abdominal)pain score,chemoembolization syndrome,quality of life score,TCM syndrome score,liver function and AFP and other indicators of the two groups before and after treatment were statistically analyzed,and spss21.0 software package was used for statistical processing.Results:(1)Quality of life evaluation: the quality of life score of the observation group was significantly improved,which was better than that of the control group.The difference between the two groups was statistically significant(P < 0.05).(2)the symptoms of chemoembolization syndrome:after treatment,the pain,fever,nausea and vomiting degree and duration of the observation group were lower than that of the control group,the difference was statistically significant(P < 0.05)Evaluation: after treatment,the seven scores of TCM syndromes in the observation group were significantly lower than that of the control group,the difference was statistically significant(P < 0.05),and there was no significant statistical significance for the improvement of stool(P > 0.05);the total score of TCM syndromes was significantly lower than that of the control group,and the evaluation of TCM syndrome efficacy was significantly improved compared with the control group(P < 0.05).(4)Liver function and tumor marker evaluation: there was no significant difference in liver function and tumor markers between the two groups before treatment,which was comparable(P > 0.05);after treatment,the liver function and AFP scores of the observation group were lower than that of the control group,and the difference was statistically significant(P < 0.05).Conclusion: gexiazhuyu decoction treatment group has better curative effect than conventional control group,can significantly relieve the symptoms of embolism syndrome after TACE,improve liver function,reduce tumor markers,and improve the quality of life of patients.For patients with TACE syndrome after primary liver cancer,the treatment is simple and effective,and has certain clinical application value.